Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

cardiopulmonology

- PMLiVE

Sanofi and Owkin expand AI collaboration to include drug positioning in immunology

The expansion builds on the companies’ strategic alliance previously announced in 2021

- PMLiVE

AbbVie and Tentarix partner to develop oncology and immunology biologics

The collaboration will use Tentarix's proprietary platform to develop biologics against two targets

- PMLiVE

‘Click chemistry’ system used to map new class of drug targets in cancer and immunology

The novel tagging system won the Nobel Prize in Chemistry in October 2022

- PMLiVE

AstraZeneca and Cellectis enter gene therapy partnership worth over $2.2bn

The deal gives AZ access to Cellectis’ gene editing technologies and manufacturing capabilities

- PMLiVE

Merck announces partnerships worth $1.3bn with BenevolentAI and Exscientia

The deals aim to accelerate drug development in oncology, neurology and immunology

- PMLiVE

Eli Lilly to acquire Dice Therapeutics for approximately $2.4bn

The deal marks a significant expansion to Lilly's immunology pipeline

- PMLiVE

Enzyvant and Altavant announce merger to accelerate rare disease therapies

The combined company is in the process of developing in-house manufacturing

- PMLiVE

Sanofi and IGM Biosciences agree on deal potentially worth over $6bn

The deal focuses on research into oncology, immunology and inflammation targets

- PMLiVE

Lilly to target difficult-to-treat disease through tie-up with Lycia

Lilly will use Lycia Therapeutics’ novel technology to inhibit “intractable” targets in its therapeutic areas of focus, including immunology and pain

- PMLiVE

The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor

Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals how life...

Avalere Health

- PMLiVE

Biogen doses first patient in phase 3 systemic lupus erythematosus study

Biogen has initiated the late-stage study based on positive results from the phase 2 LILAC study

- PMLiVE

Sanofi pays $160m upfront to acquire Tidal Therapeutics

French pharma company's acquisition of pre-clinical stage biotech includes mRNA-based research platform

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links